This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

This study has been withdrawn prior to enrollment.
Mayo Clinic
Information provided by (Responsible Party):
Novartis Identifier:
First received: January 13, 2006
Last updated: March 2, 2016
Last verified: March 2016
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia

Condition Intervention Phase
Constipation and Dyspepsia Drug: Tegaserod and Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To determine the effect of one week of tegaserod on the passage of content through the gut by radiological procedures.

Secondary Outcome Measures:
  • To evaluate the PD effects of tegaserod on upper & lower GI transit
  • To evaluate global well-being & upper and lower GI symptoms in daily assessment of bowel habits and weekly global and individual symptom assessments

Enrollment: 0

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females aged 18 to 64 years of age
  • Patients must present with two or more of the following criteria for chronic constipation for at least 12 weeks prior to entering the study:

    1. Less than 3 bowel movements per week
    2. Hard or lumpy stools
    3. Straining during bowel movements
    4. Feeling of incomplete evacuation
  • Patients must report overlapping symptoms consistent with dyspepsia, such as mid-upper abdominal discomfort characterized by early satiety, post-meal fullness and bloating

Exclusion Criteria:

  • Patients with a recent history of, or current frequency of diarrhea occuring more than once per month off of laxatives
  • Clinically significant diagnosis of pelvic outlet obstruction or pelvic floor dyssenergia as determined by the study physicians
  • Patients with constipation secondary to medication use as determined by the study physician
  • Patients with clinically significant abnormal TSH levels at screening
  • Patients that have heartburn or abdominal pain as their predominant GI symptom
  • Evidence of cathartic colon or a history of laxative abuse

    • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277550

Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Nicholas Talley, MD Mayo Clinic
Principal Investigator: Michael Crowell, PhD Mayo Clinic
  More Information

Responsible Party: Novartis Identifier: NCT00277550     History of Changes
Other Study ID Numbers: CHTF919EUS42
Study First Received: January 13, 2006
Last Updated: March 2, 2016

Keywords provided by Novartis:
Constipation, Tegaserod, Dyspepsia

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 19, 2017